Literature DB >> 26967368

Evaluation of the Alere i Influenza A&B assay for rapid identification of influenza A and influenza B viruses.

Flavia Cecilia Chiarella1, Esther Culebras1, Manuel Enrique Fuentes-Ferrer2, Juan José Picazo1.   

Abstract

The Alere i Influenza A&B assay is a novel isothermal nucleic acid amplification assay capable of detecting and differentiating influenza A and B viruses in approximately 15 min with minimal hands-on time. This study was conducted in order to assess the performance of the Alere i Influenza A&B assay compared to molecular techniques, considered to be gold standard methods, to evaluate the results. A total of 119 nasopharyngeal swabs collected from inpatients with influenza-like illness were included in the study using both archived and prospectively collected samples from adults and children. Prospectively collected samples were also compared to the Alere BinaxNOW® Influenza A & B Card. The overall sensitivity for detection of influenza A and B viruses compared to those of molecular techniques were 65.96 % and 53.33 % respectively, while the specificity was 98.51 % and 95.96 %. Compared to the Alere BinaxNOW® Influenza A & B Card, the Alere i assay is considerably more sensitive for detection of influenza A and B viruses, although both tests demonstrated excellent specificity for diagnosis of influenza viruses.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26967368     DOI: 10.1099/jmm.0.000249

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

2.  Paying for Point-of-Care Nucleic Acid Amplification Tests: a Micro-Comic Strip.

Authors:  Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

3.  Accurate PCR Detection of Influenza A/B and Respiratory Syncytial Viruses by Use of Cepheid Xpert Flu+RSV Xpress Assay in Point-of-Care Settings: Comparison to Prodesse ProFlu.

Authors:  Daniel M Cohen; Jennifer Kline; Larissa S May; Glenn Eric Harnett; Jane Gibson; Stephen Y Liang; Zubaid Rafique; Carina A Rodriguez; Kevin M McGann; Charlotte A Gaydos; Donna Mayne; David Phillips; Jason Cohen
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

4.  Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test.

Authors:  Hongmei Wang; Jikui Deng; Yi-Wei Tang
Journal:  Expert Rev Mol Diagn       Date:  2018-04-24       Impact factor: 5.225

Review 5.  Cost-Effective Respiratory Virus Testing.

Authors:  B A Pinsky; R T Hayden
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

6.  Use of Saliva Swab for Detection of Influenza Virus in Patients Admitted to an Emergency Department.

Authors:  Alicia Galar; Pilar Catalán; Lara Vesperinas; Iria Miguens; Ioana Muñoz; Alejandro García-Espona; José Antonio Sevillano; Juan Antonio Andueza; Emilio Bouza; Patricia Muñoz
Journal:  Microbiol Spectr       Date:  2021-08-25

7.  The impact of point-of-care testing for influenza A and B on patient flow and management in a medical assessment unit of a general hospital.

Authors:  S O'Connell; C Conlan; M Reidy; C Stack; A Mulgrew; J Baruah
Journal:  BMC Res Notes       Date:  2020-03-10

8.  Comparison of the ID Now Influenza A & B 2, Cobas Influenza A/B, and Xpert Xpress Flu Point-of-Care Nucleic Acid Amplification Tests for Influenza A/B Virus Detection in Children.

Authors:  Neena Kanwar; Jeffrey Michael; Kathryn Doran; Emily Montgomery; Rangaraj Selvarangan
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.